Norway· NO-ID_BD1333F7-2611-44CB-AC90-1B656145A20C
Kymriah
A tisagenlecleucel product containing tisagenlecleucel, registered in Norway by Novartis Europharm Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Tisagenlecleucel is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XL04 (tisagenlecleucel), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Tisagenlecleucel · ATC L01XL04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Tisagenlecleucel
- Manufacturer
- Novartis Europharm Limited
- Country
- Norway (NO)
- ATC code
- L01XL04
- ATC class
- Tisagenlecleucel
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 2
1 priced- no_merkevare_idID_BD1333F7-2611-44CB-AC90-1B656145A20C
- no_varenummer3939431NOK 3159899
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for tisagenlecleucel.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tisagenlecleucel · interactions on record
60 records
- 28 severe
- 32 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tisagenlecleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKYMRIAHNovartis Pharmaceuticals Corporation
- FranceKYMRIAH 1,2 x 1 000 000 - 6 x 100 000 000 cellules, dispersion pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- SwitzerlandKymriah, Zellsuspension zur InfusionNovartis Pharma Schweiz AG
- CzechiaKYMRIAHNovartis Europharm Limited, Dublin
- SpainKYMRIAH 1,2 x 10e6 - 6,0 x 10e8 celulas dispersion para perfusionNovartis Europharm Limited
- FinlandKymriahNovartis Europharm Limited
- BelgiumKymriah 1,2 x 10*6 – 6 x 10*8 cellsNovartis Europharm
- United KingdomKymriah 1.2million-600million cells dispersion for infusion bagsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kymriah
- Liechtenstein · Kymriah
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8344a1f2-4148-4c36-b304-96bbbb0b3e2d GET /v1/drugs/8344a1f2-4148-4c36-b304-96bbbb0b3e2d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Infusjonsvæske, dispersjon",
"source": "fest",
"status": "A",
"atc_name": "Tisagenlekleucel",
"merkevare_id": "ID_BD1333F7-2611-44CB-AC90-1B656145A20C",
"name_form_strength": "Kymriah inf, disp",
"prescription_group": "C"
}See everything about tisagenlecleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.